Archive — US — techcrunch
Science Corporation implants its vision-restoring chip in its first Stargardtdisease patient
Science Corporation has successfully implanted its vision-restoring chip, PRIMA, into its first Stargardt disease patient, aiming to restore central vision. The device transmits signals from a camera-equipped glasses to a chip implanted in the eye. CEO Max Hodak envisions broader applications of brain-computer interfaces (BCIs) for various medical conditions beyond visual impairments.
Key points
- Science Corporation's CEO Max Hodak announced the implantation of the PRIMA chip in a Stargardt disease patient.
- Stargardt disease causes gradual central vision loss; currently considered incurable.
- The PRIMA device acts as artificial photoreceptors, transmitting visual signals to the optic nerve using camera-equipped glasses.
- The initial patient rehabilitation showed positive results with visible letters and words.
- Future improvements of the device are aimed at creating a larger field of view and enhancing detail.
- Science Corporation's long-term goal includes developing BCIs for neurology and addressing various medical conditions.
Why it matters
- This development represents a significant milestone in the application of brain-computer interface technology, which aligns with current trends in neurotechnology and biomedical advancements.
- As of 2025, BCIs are becoming integral in treating neurological diseases, reflecting a shift toward integrating technology with healthcare.
- Neuralink's prior work in BCIs sets a foundational context for ongoing developments, especially under the direction of industry leaders like Hodak.
The successful implantation of the PRIMA chip marks a pioneering step in restoring vision for Stargardt disease patients, signifying a broader potential for BCIs in healthcare and shaping future advances in neurological treatments.